chrisvoncsefalvay/vaers-outcomes huggingface dataset:
creating shingles/pityriasis type reaction; creating shingles/pityriasis type reaction; nerve ending pain, nerve pain,; nausea; itchy rashes on feet; body aches; chills.; fatigue; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on an unknown date in Apr2021 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Medical history included blood pressure and herpes. Concomitant medication included hydrochlorothiazide (MANUFACTURER UNKNOWN) for an unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 23Apr2021 at 07:00, the patient experienced shingles/pityriasis type reaction, nerve ending pain, nerve pain, nausea, itchy rashes on feet. It was reported that nine days of all symptoms. The patient also experienced body aches, chills and fatigue. The events resulted in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were taken for the reported events and included treatment with steroid cream for feet, and now acyclovir from the patient. On 02May2021, the patient underwent rapid and full nasal swab COVID-19 test and the result was negative. The clinical outcome of the events creating shingles/pityriasis type reaction, nerve ending pain, nerve pain, nausea, itchy rashes on feet, body aches, chills and fatigue was not recovered at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
12 mo seen for WCC - healthy - developed a "small red circular" lesion in face that spread to trunk. Patient never seen. Mother called with concerns. No fever, no change in appetite and energy level. Non-pruritic. Diagnosis: measles-like reaction.
Patient complained of the injection site being red and a lump occurring.  She also got diarrhea and has had it for the past five days.
Received the Johnson and Johnson vaccine April 2021.  I experienced a DVT (blood clot) the full length of my leg in January 2023.   I have no other risk factors and doctors have been unable to determine the cause of my incident.   J & J vaccines have had incidents of blood clots raising my suspicion for possible vaccine injury.
Is there a possibility that the vaccines cause muscular spasms and twitching as I have experienced after the last vaccine.; Is there a possibility that the vaccines cause muscular spasms and twitching as I have experienced after the last vaccine.; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A patient (no qualifiers provided) received BNT162b2 (BNT162B2), as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1, Manufacturer Unknown), for Covid-19 immunization; Covid-19 vaccine (DOSE 2, Manufacturer Unknown), for Covid-19 immunization; Covid-19 vaccine (DOSE 3 (BOOSTER), Manufacturer Unknown), for Covid-19 immunization.  The following information was reported: MUSCLE SPASMS (non-serious), MUSCLE TWITCHING (non-serious), outcome "unknown" and all described as "Is there a possibility that the vaccines cause muscular spasms and twitching as I have experienced after the last vaccine.".  Additional Information: The patient had taken 2-vaccines and 2-boosters and about to take 3rd of the bivariant against omicron. The patient was questioning that whether there is a possibility that the vaccines cause muscular spasms and twitching as the patient had experienced after the last vaccine and also questioned can these symptom get worse with continued use of Pfizer boosters.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Peeling of ears, hands and knees. No treatment needed. Follow up visit if not resolve.
pt seen in office 20AUG98 w/ c/o burning painful from knees distal that progressed to numbness & tingling several days p/vax;fever 101.2 19AUG98;also has devel  productive cough;
PATIENT RECIEVED VACCINE ON FEBRUARY 12, 2021. BEGAN FEELING VERY FATIGUED AND SHORT OF BREATH ABOUT ONE WEEK LATER. AFTER A WEEK OF FEELING UNWELL SHE DECIDED TO GO TO LOCAL CLINIC. THEY DID AN EKG AND SENT FOR A HEART MONITOR. SHE WAS SENT HOME AND WAITED FOR THE MONITOR TO ARRIVE BY MAIL. IN ABOUT ANOTHER  WEEKS TIME SHE WAS RUSHED TO EMERGENCY AND WAS HAVING A MASSIVE HEART ATTACK. SHE PASSED AWAY MARCH 2, 2 1/2 WEEKS AFTER HER FIRST MODERNA VACCINE. I BELIEVE IT WAS THE VACCINE THAT CAUSED THE HEAT ATTACK.
This spontaneous report was received from a pharmacist, referring to a patient of unknown age and gender. No medical history or concurrent conditions were reported. On 21-OCT-2015, the patient was vaccinated with an improperly stored dose of GARDASIL (lot # J01537, expiration date: 09-APR-2016) (dose, route and strength were not provided). Concomitant medication was not provided. No adverse effects were reported. It was also reported that temperature was -0.1 degrees C, time frame was 15 minutes and it was not previous temperature excursion. This is one of several cases from the same reporter. Additional information has been requested.
This case was reported by a consumer via call center representative and described the occurrence of pain in arm in a 70-year-old female patient who received SHINGRIX for prophylaxis. On 21st July 2018, the patient received the 1st dose of SHINGRIX (intramuscular). On 21st July 2018, less than a day after receiving SHINGRIX, the patient experienced pain in arm, injected limb mobility decreased, difficulty sleeping and injection site erythema. The patient was treated with Ice Pack (Nos). On an unknown date, the outcome of the pain in arm, injected limb mobility decreased, difficulty sleeping and injection site erythema were recovered/resolved. It was unknown if the reporter considered the pain in arm, injected limb mobility decreased, difficulty sleeping and injection site erythema to be related to SHINGRIX. Additional details were reported as follows: The patient received SHINGRIX on an unknown arm. The patient's arm was very painful and she could not move it. The patient also had redness at the injection site, but no swelling was reported. The patient put an ice pack on her arm, but it was painful enough to make it difficult to sleep.
flu; Initial information received on 12-Dec-2021 regarding an unsolicited valid  non-serious case received from a consumer or non-healthcare professional.  This case involves a 23 years old male patient who had flu (influenza) after receiving INFLUENZA QUADRIVALENT RECOMBINANT VACCINE [FLUBLOK QIV].  It was unknown if the patient had any medical history, concomitant disease or risk factor  The patient's medical treatment(s), vaccination(s) and family history were not provided.  On 05-Oct-2021, the patient received a 0.5 ml total of suspect INFLUENZA QUADRIVALENT RECOMBINANT VACCINE [frequency : once, lot U7328DA, expiry date : 30-jun-2022] via intramuscular route in unknown administration site for prophylactic vaccination.  On 12-Dec-2021, the patient developed a non-serious flu (influenza) 2 months 7 days following the administration of INFLUENZA QUADRIVALENT RECOMBINANT VACCINE.  It was reported "He is my son and he was tested positive for the flu at the Hospital on 12-Dec-2021."  It was unknown if the patient experienced any additional symptoms/events  Relevant test was included- 12-Dec-2021- tested positive for the flu.   It was not reported if the patient received a corrective treatment for the event.  At time of reporting, the patient recovering for the reported event.
Information has been received from a physician concerning a female patient who in approximately 2007 ("about 4 years ago") was vaccinated with a full series of RECOMBIVAX HB (dose, route and lot # not reported). The physician reported that in approximately 2009 and ("about 1 and 1/2 years ago") last titers were taken. The patient's HBs titers were under 10. It was unspecified if the patient sought medical attention. At the time of reporting, the patient's status was unknown. No further information is available.
Vaccines given at 11am 04/09/21.  At 4pm 04/09/21 the patient mother called and said the infants left hand is swelling and he has a rash on his head, no difficulty breathing.  RN instructed the mother to take the infant to the ER.  At ER, it was determined that he was having an allergic reaction and was given steroids, epinephrine and Benadryl.  Patient was back at home same day at 7pm and  mother said there was no further problems noted.  RN called the patients mother the next day 04/10/21 and the mother said he is fine with no other problems.  The mother said she plans to take the infant to follow up with Pediatrician on Monday 04/12/21.
Moderna COVID-19 Vaccine mRNA (PF) 100 mcg/0.5mL 1/22/2021        Dose Site Route Manufacturer Lot # Product    1/22/2021 Given  RD IM  042L20A     rash at site 8cm round erythemic
Soreness at injection site (upper left arm); This is a spontaneous report from a non-contactable consumer, the patient. A 64-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3247) via an unspecified route of administration in the left arm on 04Mar2021 at 10:15 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. Medical history included peripheral neuropathy and high cholesterol. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. On 04Mar2021, the patient experienced soreness at injection site (upper left arm). The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event soreness at injection site (upper left arm) was recovered on unknown date in Mar2021.  No follow-up attempts are possible. No further information is expected.
My entire body really ached. I was freezing. I was feeling absolutely miserable. Very physically uncomfortable. No appetite whatsoever. I was feeling close nauseated. I almost felt shaky. I took an Advil about four hours later and I felt a little better. I had diarrhea that afternoon. I turned up the heat and started drinking chamomile tea to warm up. I didn't eat anything anything until about 6:00, when I had toast and banana. Feelin 95% better by Monday.
Got shingles this year on her forehead / Suspected vaccination failure; Got shingles this year on her forehead; Blister; Tingling pain down her face; Tingling pain down her face; This serious case was reported by a physician via sales rep and described the occurrence of vaccination failure in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   Concurrent medical conditions included covid-19.   On an unknown date, the patient received the 2nd dose of Shingrix and the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix and Shingrix, the patient experienced vaccination failure (Verbatim: Got shingles this year on her forehead / Suspected vaccination failure) (serious criteria GSK medically significant), shingles (Verbatim: Got shingles this year on her forehead), blister (Verbatim: Blister), facial pain (Verbatim: Tingling pain down her face) and tingling (Verbatim: Tingling pain down her face). The outcome of the vaccination failure was unknown and the outcome of the shingles, blister, facial pain and tingling were resolved (duration 3 weeks).   It was unknown if the reporter considered the vaccination failure, shingles, blister, facial pain and tingling to be related to Shingrix and Shingrix.     It was unknown if the company considered the vaccination failure, shingles, blister, facial pain and tingling to be related to Shingrix and Shingrix.   Additional Information: GSK receipt date: 22-May-2023 The physician gave the Shingrix vaccine during Covid, and then got shingles this year on her forehead.  The physician reporter that the patient had mild with only two blisters and had slight tingling pain down her face.  The physician reporter events only lasted about 3 weeks.  The physician thought it would have been way worse if she not gotten Shingrix. This case was considered as suspected vaccination failure since the details regarding time to onset and laboratory confirmation of shingles were unknown at the time of reporting.
The patient received a dose of the vaccine following temperature excursions on unknown dates; No adverse event; This spontaneous report as received from a medical assistant refers to a current 6-month-old patient of unknown gender.  The patient's concurrent conditions, medical history and concomitant medications were not provided.   On an unknown date, the rotavirus vaccine, live, oral, pentavalent (ROTATEQ)  (lot # S013439 with expiration date 03-MAR-2021, lot # S013436 with expiration date 30-JAN-2021, and lot # S006050 with expiration date 12-DEC-2020) underwent a temperature excursion.   Temperature Total Time and LOWEST Temperature BELOW 36°F/2°C (0C) Time frame 7 hours 30 minutes Previous temperature excursion? yes, Total Time and LOWEST Temperature BELOW 36°F/2°C (0C) for 8 hours 30 minutes Was call because of a "data logger"? yes  On an unknown date, the patient was vaccinated with rotavirus vaccine, live, oral, pentavalent (ROTATEQ) at a dose of 2 ml (route not provided) as prophylaxis. No adverse events were reported.  This is one of several reports received from the same reporter  This spontaneous report as received from a other health professional refers to a patient of unknown age.    On an unknown date the patient was vaccinated with rotavirus vaccine, live, oral, pentavalent (ROTATEQ) lot # S006050, 2 milliliter for prophylaxis.       On an unknown date the patient experienced product storage error and no adverse event.    The outcome of product storage error and no adverse event is unknown.   The reporter considered product storage error and no adverse event to be not assessed to Rotavirus Vaccine, Live, Oral, Pentavalent(ROTATEQ).     {Additional information has been requested. / Additional information is not expected.}; Sender's Comments:  US-009507513-2005USA003382: US-009507513-2005USA004545: US-009507513-2005USA004950: US-009507513-2005USA004951: US-009507513-2005USA004952: US-009507513-2005USA004953: US-009507513-2005USA004954: US-009507513-2005USA004955: US-009507513-2005USA004956: US-009507513-2005USA004957: US-009507513-2005USA004958: US-009507513-2005USA004960: US-009507513-2005USA004961: US-009507513-2005USA004962: US-009507513-2005USA004963: US-009507513-2005USA004964: US-009507513-2005USA004965: US-009507513-2005USA004966: US-009507513-2005USA004967: US-009507513-2005USA004968: US-009507513-2005USA004969: US-009507513-2005USA004970: US-009507513-2005USA004971: US-009507513-2005USA004972: US-009507513-2005USA004973: US-009507513-2005USA004974: US-009507513-2005USA004975: US-009507513-2005USA004976: US-009507513-2005USA004977: US-009507513-2005USA004978: US-009507513-2005USA004979: US-009507513-2005USA004980: US-009507513-2005USA004981: US-009507513-2005USA004982: US-009507513-2005USA004983: US-009507513-2005USA004984: US-009507513-2005USA004985: US-009507513-2005USA004986: US-009507513-2005USA004987: US-009507513-2005USA004988: US-009507513-2005USA004989: US-009507513-2005USA004990: US-009507513-2005USA004991: US-009507513-2005USA004992: US-009507513-2005USA004993:
Headache/ headache never let up during the 25 days; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (Headache/ headache never let up during the 25 days) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 036B21A and 001A21A) for COVID-19 vaccination.     Concurrent medical conditions included Hyperlipidemia since 02-Feb-2010, Hypertension since 02-Feb-2010, Osteoporosis since 02-Feb-2010, Irritable bowel syndrome (IBS) since 02-Feb-2010, Chronic kidney disease since 19-Feb-2014, Latex allergy, Allergy to plants (Allergy to Mushrooms), Drug allergy (Allergy to Sulfa), Drug allergy (Allergy to Aspirin), Drug allergy (Allergy to Lisinopril), Drug allergy (Allergy to Amlodipine), Drug allergy (Allergy to Nsaids), Drug allergy (Allergy to Benadryl), Drug allergy (Allergy to Fenofibrate), Drug allergy (Allergy to Simvastatin), Allergy to antibiotic (Allergy to Erthromycin), Allergy to antibiotic (Allergy to Tetracycline) and Allergy to antibiotic (Allergy to Metronidazole). Concomitant products included VENLAFAXINE for Fibromyalgia, METOPROLOL TARTRATE and OLMESARTAN MEDOXOMIL for Hypertension, CHLORTHALIDONE for Kidney disorder, CYCLOBENZAPRINE HYDROCHLORIDE for Muscle spasm.   On 06-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 14-Apr-2021, the patient experienced HEADACHE (Headache/ headache never let up during the 25 days). The patient was treated with PARACETAMOL (TYLENOL EXTRA STRENGTH) for Headache, at a dose of 1 dosage form every six hours. At the time of the report, HEADACHE (Headache/ headache never let up during the 25 days) had resolved.            Action taken with mRNA-1273 in response to the events was not applicable.   This case was linked to US-MODERNATX, INC.-MOD-2021-106233 (E2B Linked Report). This case was linked to MOD-2021-106439 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 06-Jun-2021: Follow-up information received on 06-JUN-2021 contains significant information: Added patient demographics, relevant medical history (allergies and current conditions), 1st dose and 2nd dose vaccine information, concomitant  medications and treatment medication. The outcome of the event (Headache) changed from unknown to resolved.; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-106233:
Site: Pain at Injection Site-Mild, Systemic: near syncope-Medium, Systemic: Hypotension-Medium, Systemic: Weakness-Medium
12/05/06 Pt. called had flu shot on 11/29/06.  Has had muscle soreness in left upper arm down to forearm since.  Denies redness, swelling, fever.  Pt. said she exercised arm after injection and I told her this could have aggravated area.  Pt. to call back if she continues to have problems.  1/2/07 Called pt. back re: left arm.  Says she is still having muscular pain, described as a "toothache" type pain that has awakened her at night-she describes this as a deep muscle ache.  She says that pain has gotten better, but she notices it more when she goes to put on her seat belt and has to reach across to put on her seat belt.  Advised pt. to see her PCP, but she has Medicare and says that the co-pay is too much (when inquired, pt. told me it is $15)-she is concerned about cost of any tests that may be incurred.  Explained that it was very important to see a physician, especially since it has been over a month since the injection was given.  Pt. voiced understanding, but is afraid of costs she may incur.  She says it has not affected her work (she is retired and only works occasionally).  Asked pt. to call me back in 2 weeks if I had not called her back.
Patient received Moderna vaccine but is not in recommended age range.  Patient is on 13 years old.  Guardian was notified of the mistake by a physician and was advised of what to watch for.
Severe pain in muscle where injected, fever, swelling, throbbing, concentrated rash, all symptoms constant. Right deltoid area rash, swelling, & tenderness extending to axilla.
From 8 hours to aprox 60 hours post vaccine headache, chills and hot flashes, extreme fatigue and nausea. It was bad enough to take two afternoons off work and Tylenol helped but did not fix the issue.  Exhaustion has persisted into day 5 and I've been needing frequent rest breaks.
Pt reports receiving Covid-19 vaccine on 1/9/2021 on left arm. She states that "immediately" after she received vaccine she felt "tongue tingling". About 10 min later she felt "lip tingling" and started to develop "large red bump" at injection site. She advised nurse observing patients and physician on site was advised. Pt reports she was administered EPI and Benadryl IM and "felt better almost immediately". Pt states "tingling" resolved within the hour and she felt "scalded tongue" for about 24 hrs. Large local reaction slowly resolved over a 3 day period. She denies any visible skin rash / hives or AE. No throat sx. No resp sx. No GI sx. Pt denies a hx of adverse reactions to any injected medication or to any vaccine in the past.   *Neg hx of Covid - 19 infection
Information has been received from a physician and a medical assistant concerning a 33 year old female patient who on 19-AUG-2009 was vaccinated with the first 0.5 ml doe of GARDASIL (lot # 0670Y). Subsequently, the patient was diagnosed with a single, pinpoint condyloma on the perineum on 20-OCT-2009. The condyloma was excised in the office on that date. Since July 2009 the patient had a new sexual partner. The patient sought unspecified medical attention. At the time of the report, the patient had not recovered. Follow up information has been received from the physician concerning the 33 year old female patient with no illness at the time of vaccination and no known allergies, birth defects or medical conditions reported, who on 19-AUG-2009 was vaccinated with the first 0.5 ml dose of GARDASIL (route unknown, lot # 0670Y) at the private doctor's office with private funds. The physician reported that the patient broke out with condyloma shortly after GARDASIL. The physician stated that it was confirmed Condyloma acuminatum on 20-OCT-2009. Additional information has been requested.
Starting seeing flashes of light which got progressively worse - could not drive. Then got a headache and was in bed for the afternoon.
After received my 2nd shot  I went into a deep depression that I am still struggling to get out of. Additionally, since getting the second shot I have gained 45lbs. In approx 16 months.
Patient received Moderna COVID19 vaccine on 3/11. Upon entering patient vaccine it was noted that she had already completed her COVID19 vaccine series of Pfizer in February.
Nosebleed immediately after FLUMIST for 3-5 minutes, resolved spontaneously.